SCHEDULE: Soleus Group Discloses 9.99% Stake in Aprea Therapeutics

Soleus Private Equity and affiliated entities, including Guy Levy, have disclosed a 9.99% beneficial ownership stake in Aprea Therapeutics, Inc. through warrants.

Summary

• Soleus Private Equity Fund III, L.P. and its affiliated entities, along with Guy Levy, have disclosed beneficial ownership in Aprea Therapeutics, Inc. via a Schedule 13G.
• The Soleus group collectively beneficially owns 1,271,080 shares of Aprea Therapeutics' Common Stock.
• This ownership represents 9.99% of the outstanding Common Stock, calculated based on 11,452,452 shares outstanding as of March 16, 2026.
• The shares are issuable upon the exercise of pre-funded warrants and common warrants held by Soleus Private Equity Fund III, L.P. and Soleus Capital Master Fund, L.P.
• The reporting persons disclaim beneficial ownership of these shares except for the purpose of determining their obligations under Section 13(d) of the Exchange Act.
• The acquisition was not for the purpose of changing or influencing control of Aprea Therapeutics.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor has taken a substantial passive stake, indicating potential long-term confidence in Aprea Therapeutics, though without active engagement.

Positives

• A significant institutional investor group, Soleus, has taken a substantial passive stake, potentially signaling confidence in Aprea Therapeutics.
• The investment is structured through warrants, which could provide future capital to Aprea Therapeutics upon exercise, though this disclosure does not detail specific warrant terms or exercise plans.

Risks

• The beneficial ownership is derived from warrants, meaning the actual common stock shares are not yet held and their exercise is subject to warrant terms and beneficial ownership limitations.
• The reporting persons explicitly disclaim beneficial ownership for purposes other than Section 13(d) obligations, indicating a passive investment without intent to influence control or management.

Future Outlook

This disclosure of beneficial ownership does not contain forward-looking statements or guidance from Aprea Therapeutics or the reporting persons regarding the issuer's future performance.

Management Comments

• No direct quotes or paraphrased statements from company management of Aprea Therapeutics are present.
• The Soleus reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing the control of Aprea Therapeutics.

Industry Context

StockSavvy.ai notes that institutional investor filings like this Schedule 13G are common disclosures. A 9.99% stake, while significant, is typically considered a passive investment, especially given the explicit disclaimer regarding intent to influence control. This type of investment by a private equity group in a biotechnology company like Aprea Therapeutics suggests a long-term view on the company's potential, often related to its drug pipeline or market position, without seeking active management involvement.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of a passive ownership stake. It does not provide performance metrics for comparison to industry standards or specific comparable companies or projects.
• The 9.99% stake is just below the 10% threshold that would typically trigger a Schedule 13D filing, which implies a more active investment intent.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake might be viewed positively, potentially increasing investor confidence.
• Company Management: Awareness of a large passive investor on the cap table.

Next Steps

• This disclosure does not explicitly mention future actions or milestones for Aprea Therapeutics.
• The reporting persons will continue to monitor their investment and file amendments to Schedule 13G as required by changes in their beneficial ownership.

Key Dates

Recommendation

The filing indicates a significant, passive institutional investment in Aprea Therapeutics by the Soleus group. While this signals a degree of confidence from a sophisticated investor, the filing itself does not provide new operational or financial performance data for Aprea Therapeutics that would warrant a 'buy' or 'sell' recommendation. The investment is through warrants, which implies a future potential for conversion. Given the passive nature and lack of new fundamental information, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while awaiting further operational updates from Aprea Therapeutics.

Keywords

Aprea Therapeutics, Soleus Private Equity, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Equity Stake, Biotechnology, Pharmaceuticals